Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ulotaront
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : $30.0 million
Deal Type : Licensing Agreement
Otsuka and Sumitomo Revise License Agreement
Details : Under the license agreement, Otsuka holds exclusive rights to develop, manufacture, and commercialize SEP-363856 (ulotaront), TAAR1 agonist. It is being evaluated with the patient for Schizophrenia.
Product Name : SEP-363856
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 15, 2024
Lead Product(s) : Ulotaront
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : $30.0 million
Deal Type : Licensing Agreement
Details : Gemtesa (vibegron) is a once-daily beta-3 adrenergic receptor (β3) agonist, is currently under investigation for the treatment of men with overactive bladder (OAB) symptoms receiving pharmacological therapy for benign prostatic hyperplasia.
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2023
Lead Product(s) : Relugolix,Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Sumitomo Pharma and Pfizer in Canada Receive Health Canada Approval for MYFEMBREE®
Details : Myfembree (relugolix, estradiol, and norethindrone acetate) has received a dual indication approval, making it the first Health Canada-approved oral treatment to manage uterine fibroids and endometriosis.
Product Name : Myfembree
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2023
Lead Product(s) : Relugolix,Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ulotaront
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SEP-363856 (ulotaront) is a TAAR1 agonist with 5-HT1A agonist activity, is currently under investigation for the treatment of schizophrenia, generalized anxiety disorder and the adjunctive treatment of MDD with additional indications under consideration.
Product Name : SEP-363856
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 31, 2023
Lead Product(s) : Ulotaront
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TP-3654
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TP-3654 is an oral investigational inhibitor of PIM kinases, which has potential antitumor and anti-fibrotic effects through multiple pathways, including induction of apoptosis.
Product Name : TP-3654
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2022
Lead Product(s) : TP-3654
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TP-1287 is enzymatically cleaved, yielding active moiety, potent inhibitor of CDK9. Inhibiting CDK9 is thought to downregulate transcription of target genes, including MCL-1, reducing leukemic blast viability in MCL-1–dependent hematologic malignancies...
Product Name : TP-1287
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2022
Details : DSP-0390 is an investigational emopamil-binding protein (EBP) inhibitor. EBP is an endoplasmic reticulum membrane protein involved in cholesterol biosynthesis.
Product Name : DSP-0390
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 18, 2022
Details : Under the agreement, Jazz will receive an exclusive license to develop and commercialize narcolepsy and sleep drug DSP-0187/JZP441 in U.S., Europe and other territories except Japan, China and other Asia/Pacific countries and regions, where Sumitomo Phar...
Product Name : JZP441
Product Type : Other Small Molecule
Upfront Cash : $50.0 million
April 05, 2022
Lead Product(s) : TP-3654
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TP-3654 is an oral investigational inhibitor of PIM kinases, which has shown potential antitumor and anti-fibrotic activity through multiple pathways, including induction of apoptosis in preclinical models.
Product Name : TP-3654
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : TP-3654
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable